Emmaus Life SciencesEMMA -7.26% Net Debt Paydown Yield % is 57.41% as of Jul. 03, 2026. The stock has 6 warning signs investors should review. Among 1,163 Biotechnology companies, Emmaus Life Sciences ranks better than 97.94% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Emmaus Life Sciences's Net Debt Paydown Yield % was 57.41%.
Emmaus Life Sciences (OTCPK:EMMA) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Emmaus Life Sciences Net Debt Paydown Yield % Related Terms
Emmaus Life Sciences Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences Net Debt Paydown Yield % Chart
EMMA vs PTIX, BZYR, RMTG: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 57.41% mean?
Emmaus Life Sciences (EMMA) has a Net Debt Paydown Yield % of 57.41% as of Jul. 03, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #24 out of 1163 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Emmaus Life Sciences' Net Debt Paydown Yield % too high?
Emmaus Life Sciences' current Net Debt Paydown Yield % is 57.41%. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. Emmaus Life Sciences' value of 57.41% is 191266.7% above this industry median. Based on the distribution chart, Emmaus Life Sciences ranks #24 out of 1163 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Emmaus Life Sciences' Net Debt Paydown Yield % compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #24 out of 1163 companies for Net Debt Paydown Yield %. This places Emmaus Life Sciences in the top 2% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. Emmaus Life Sciences' value of 57.41% is 191266.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,163 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emmaus Life Sciences's current Net Debt Paydown Yield % of 57.41% is 191266.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Net Debt Paydown Yield % is 57.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 8.5% above its estimated fair value. The current Net Debt Paydown Yield % is 57.41% and 191266.7% above the Biotechnology industry median of 0.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Net Debt Paydown Yield % is 57.41% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 